Manufacturer of Controlled Substances; Notice of Application: Morton Grove Pharmaceuticals, 17231 [2013-06332]
Download as PDF
<![CDATA[
17231
Federal Register / Vol. 78, No. 54 / Wednesday, March 20, 2013 / Notices
material are not appropriate. 72 FR 3417
(2007).
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a), and
determined that the registration of
Noramco Inc., to import the basic
classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Noramco, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–06321 Filed 3–19–13; 8:45 am]
BILLING CODE 4410–09–P
FDA approved or non-approved dosage
form for commercial distribution in the
United States.
One comment objecting to the
granting of registration as an importer of
the basic class of controlled substance
listed to this applicant and a request for
a hearing were received on December
31, 2012. The objection and request for
a hearing were withdrawn.
DEA has considered the factors in 21
U.S.C. 823(a) and § 952(a) and
determined that the registration of
Watson Pharma, Inc., to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Watson Pharma, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Registration, Watson
Pharma, Inc.
[FR Doc. 2013–06328 Filed 3–19–13; 8:45 am]
By Notice dated November 5, 2012,
and published in the Federal Register
on November 13, 2012, 77 FR 67675,
Watson Pharma, Inc., 2455 Wardlow
Road, Corona, California 92880–2882,
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
DEPARTMENT OF JUSTICE
Drug
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application:
Morton Grove Pharmaceuticals
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
srobinson on DSK4SPTVN1PROD with NOTICES
BILLING CODE 4410–09–P
II
II
II
II
The company plans to import the
listed controlled substances for
analytical testing and clinical trials.
The import of the above listed basic
classes of controlled substances will be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
VerDate Mar<14>2013
18:04 Mar 19, 2013
Jkt 229001
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on December 14, 2012,
Morton Grove Pharmaceuticals, 6451
Main Street, Morton Grove, Illinois
60053–2633, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Gamma
Hydroxybutyric Acid (2010), a basic
class of controlled substance listed in
schedule I.
The company plans to manufacture
the listed controlled substance for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 20, 2013.
Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–06332 Filed 3–19–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration:
Noramco, Inc.
By Notice dated November 1, 2012,
and published in the Federal Register
on November 9, 2012, 77 FR 67397,
Noramco, Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Codeine-N-Oxide (9053) ..............
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
Schedule
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco, Inc., to manufacture the listed
E:\FR\FM\20MRN1.SGM
20MRN1
]]>Agencies
[Federal Register Volume 78, Number 54 (Wednesday, March 20, 2013)]
[Notices]
[Page 17231]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-06332]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application:
Morton Grove Pharmaceuticals
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on December 14, 2012, Morton
Grove Pharmaceuticals, 6451 Main Street, Morton Grove, Illinois 60053-
2633, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of Gamma
Hydroxybutyric Acid (2010), a basic class of controlled substance
listed in schedule I.
The company plans to manufacture the listed controlled substance
for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substance, may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 20, 2013.
Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-06332 Filed 3-19-13; 8:45 am]
BILLING CODE 4410-09-P
